What is OKUR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OKUR?

P/E (TTM) is n/a and 52-week range is $2.13 to $5.38 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OKUR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OKUR?

The company profile lists net income (TTM) near $-141M, EPS (TTM) near $-3.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Onkure Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boulder, Colorado, US, 40.4M shares outstanding, ISIN US68277Q1058 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Onkure Therapeutics Inc

$OKUR

Health Care · Biotechnology

IR Run Scenarios

$2.41

+4.78%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 45 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

Employees

Website

onkuretherapeutics.com/

IPO

2021-04-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)